Vascular endothelial growth factor as a therapeutic target in cancer

Area of Science:

• Oncology
• Molecular Biology
• Vascular Biology

Background:

• Tumor progression and metastasis are critically dependent on angiogenesis, the formation of new blood vessels.
• Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis, essential for tumor growth.
• Elevated VEGF levels in many cancers correlate with increased vascularity, recurrence, and poorer survival.

Purpose of the Study:

• To elucidate the multifaceted roles of VEGF in angiogenesis, vascular maintenance, lymphangiogenesis, and immune function.
• To discuss the link between angiogenesis and cancer progression.
• To review therapeutic strategies targeting VEGF in cancer treatment.

Main Methods:

• Literature review of VEGF's role in physiological and pathological angiogenesis.
• Analysis of studies investigating VEGF expression in various cancer types.
• Examination of preclinical and clinical data on VEGF inhibitors.

Main Results:

• VEGF is the primary stimulator of angiogenesis, crucial for tumor vascularization.
• Targeting VEGF offers a rational approach to cancer therapy.
• VEGF inhibition can impede tumor growth by preventing neovascularization and potentially enhancing drug delivery.

Conclusions:

• Inhibiting VEGF is a validated therapeutic strategy in oncology.
• VEGF blockade can lead to regression of tumor vasculature and improved anti-tumor immune responses.
• Normalization of tumor vasculature via VEGF inhibition may enhance chemotherapy efficacy.